Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26348576 | 0.83 | ADORA1 (0.55) | CYP1A2TSHRADORA1ADORA2AYTHDC1 | |
| SCHEMBL26348815 | 0.79 | CYP1A2 (0.54) | CYP1A2TSHRADORA1ADORA2AYTHDC1 | |
| SCHEMBL24239183 | 0.79 | CYP1A2 (0.54) | CYP1A2TSHRADORA1ADORA2AYTHDC1 | |
| SCHEMBL6363954 | 0.77 | ADORA2A (0.60) | CYP1A2TSHRADORA1ADORA2ATP53 | |
| SCHEMBL23228237 | 0.77 | CYP1A2 (0.72) | CYP1A2TSHRADORA1ADORA2ACYP2D6 | |
| SCHEMBL12194505 | 0.77 | PI4KA (0.60) | CYP1A2TSHRADORA1ADORA2AYTHDC1 | |
| SCHEMBL6661513 | 0.76 | SLC29A1 (0.49) | CYP1A2TSHRADORA1ADORA2AYTHDC1 | |
| SCHEMBL12359911 | 0.74 | KDM4E (0.41) | CYP1A2TSHRADORA1ADORA2AYTHDC1 | |
| SCHEMBL6663342 | 0.74 | ADORA1 (0.45) | CYP1A2TSHRADORA1ADORA2AYTHDC1 | |
| SCHEMBL18521260 | 0.74 | CYP1A2 (0.49) | CYP1A2TSHRADORA1ADORA2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728282-B1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2023-09-28 | — | — | US | disclosed |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2023-09-28 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| EP-3936514-B1 | 3'3' CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-05-24 | — | — | EP | disclosed |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I (CZ) | 2022-05-26 | — | — | US | disclosed |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-8637533-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| US-8623881-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-01-07 | — | — | US | disclosed |
| US-8492389-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2007027248-A2 | 3', 5' - CYCLIC NUCLEOSIDE ANALOGUES FOR TREATMENT OF HCV | VALEANT RESEARCH & DEVELOPMENT (US) | 2007-03-08 | — | — | WO | disclosed |
| US-4937198-A | STAINS NUCLEIC ACIDS | BECTON, DICKINSON AND COMPANY (US) | 1990-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | CYP1A2 4475/4885TSHR 1817/4885ADORA1 34/4885 |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | CYP1A2 1905/4885TSHR 3560/4885ADORA1 231/4885 |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | STING1, CGAS, TLR9 | CYP1A2 4552/4885TSHR 3142/4885ADORA1 2287/4885 |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CYP1A2 3429/4885TSHR 3873/4885ADORA1 2913/4885 |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | CYP1A2 1844/4885TSHR 2077/4885ADORA1 32/4885 |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | CYP1A2 4870/4885TSHR 4190/4885ADORA1 1854/4885 |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | STING1, MAVS, CGAS | CYP1A2 4869/4885TSHR 4232/4885ADORA1 1736/4885 |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | CYP1A2 4059/4885TSHR 3710/4885ADORA1 163/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | CYP1A2 4059/4885TSHR 3710/4885ADORA1 163/4885 |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | STING1, CGAS, IRF3 | CYP1A2 3573/4885TSHR 4803/4885ADORA1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.